Journal Watch · Frontiers in Immunology · 2026
<i>Orientia tsutsugamushi</i> and <i>Epstein-Barr Virus</i> coinfection presenting with transient fluctuating hearing loss: a case report.
The immunological interplay between these pathogens warrants further investigation.
TL;DR
The immunological interplay between these pathogens warrants further investigation.
Key findings
- This case highlights a rare presentation of scrub typhus with EBV coinfection involving fluctuating hearing loss.
- The dramatic response to doxycycline suggests this auditory symptom may be a reversible, immune-mediated complication of <i>O. tsutsugamushi</i> infection.
- Physicians should be aware of this potential manifestation in endemic areas.
- The immunological interplay between these pathogens warrants further investigation.
What they did
Laboratory findings indicated hepatic impairment and systemic inflammation. Metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid detected <i>O. tsutsugamushi</i> and EBV. EBV serology profile (VCA-IgG+, VCA-IgM-, EBNA-IgG+) suggested viral reactivation. The patient failed to respond to initial beta-lactam antibiotic therapy but showed rapid and complete resolution of symptoms, including hearing loss, after initiation of doxycycline. At the 1-month and 3-month follow-up, audiological assessment confirmed normal hearing.
Full abstract (original)
Background: Scrub typhus, caused by the obligate intracellular bacterium <i>Orientia tsutsugamushi</i>(<i>O. tsutsugamushi</i>), is an acute febrile illness. While neurological complications are known, hearing loss is an uncommon manifestation, and coinfection with <i>Epstein-Barr virus</i>(EBV) presents unique diagnostic and pathophysiological challenges. A 58-year-old woman presented with a 5-day history of high fever, severe headache, and constitutional symptoms. She reported transient, fluctuating bilateral hearing loss. Examination revealed characteristic eschars on her legs.
What they did: Laboratory findings indicated hepatic impairment and systemic inflammation. Metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid detected <i>O. tsutsugamushi</i> and EBV. EBV serology profile (VCA-IgG+, VCA-IgM-, EBNA-IgG+) suggested viral reactivation. The patient failed to respond to initial beta-lactam antibiotic therapy but showed rapid and complete resolution of symptoms, including hearing loss, after initiation of doxycycline. At the 1-month and 3-month follow-up, audiological assessment confirmed normal hearing.
Results & conclusions: This case highlights a rare presentation of scrub typhus with EBV coinfection involving fluctuating hearing loss. The dramatic response to doxycycline suggests this auditory symptom may be a reversible, immune-mediated complication of <i>O. tsutsugamushi</i> infection. Physicians should be aware of this potential manifestation in endemic areas. The immunological interplay between these pathogens warrants further investigation.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1750100 · PubMed 41972180.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
The immunological interplay between these pathogens warrants further investigation.
What type of study is this?
It is a case report / series, published in Frontiers in Immunology in 2026. Laboratory findings indicated hepatic impairment and systemic inflammation.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1750100. PubMed ID: 41972180. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/lt-i-gt-orientia-tsutsugamushi-lt-i-gt-and-lt-i-gt-epstein-barr-virus-lt-750100/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides